(ACL:Australian Stock Exchange Ltd)
Transactions by ALCHEMIA LTD (ACL) in the last 6 months
Dr. Reddy's Laboratories Ltd. (BSE:500124) entered into a binding term sheet to acquire worldwide exclusive intellectual property rights of fondaparinux sodium from Alchemia Limited (ASX:ACL) for $17.5 million in cash on September 25, 2015. For the period ended June 30, 2015, Fondaparinux had revenues of $6.23 million, loss after tax of $6.22 million, total assets of $7.8 million. The sale is conditional on shareholder approval of Alchemia Limited. Shareholder approval ...
Panther Biotechnology, Inc. (OTCPK:PBYA) executed a binding term sheet to acquire Audeo Oncology, Inc. from Alchemia Limited (ASX:ACL) for $16 million in stock and milestone payments on July 1, 2015. Under the terms of the transaction, Panther will pay stock of $15 million, upon a successful listing of Panther on NASDAQ and $1 million cash milestone payment to Alchemia on commencement of a Phase III clinical trial and royalties on world-wide net sales of HyACT products. ...
|No competitor information is available for ACL.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|